Tag Archives: Beyfortus

AstraZeneca and Sanofi’s Beyfortus Receives Approval in Japan for Prophylaxis against Respiratory Syncytial Virus

(IN BRIEF) AstraZeneca and Sanofi celebrate the approval of Beyfortus (nirsevimab) in Japan by the Ministry of Health, Labour, and Welfare for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in neonates, infants, and children entering … Read the full press release

AstraZeneca to Present Data on Vaccines and Immune Therapies Portfolio at ECCMID 2023

(IN BRIEF) AstraZeneca is set to present data on its Vaccines and Immune Therapies portfolio at the European Congress of Clinical Microbiology & Infectious Diseases. Among the data to be presented will be details on the progress of AstraZeneca’s Vaccines … Read the full press release

Sanofi gains full control of nirsevimab in US with new contractual agreements

(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release